E. COLI PATHOTYPES: COMPREHENSIVE CLASSIFICATION & TREATMENT GUIDE
Clinical Reference for Physicians
TABLE 1: E. COLI PATHOTYPES - CLASSIFICATION & ANTIBIOTIC TREATMENT
| Abbreviation | Full Name | Primary Disease(s) | Key Clinical Features | Antibiotic Treatment | Treatment Rationale |
|---|---|---|---|---|---|
| STEC / EHEC | Shiga Toxin-Producing E. coli / Enterohemorrhagic E. coli | Hemorrhagic colitis, Hemolytic Uremic Syndrome (HUS) | Bloody diarrhea, severe abdominal cramps, minimal fever. Most common serotype: O157:H7 | CONTRAINDICATED ❌ | Antibiotics increase HUS risk 14-fold by triggering toxin release. NO clinical benefit. |
| ETEC | Enterotoxigenic E. coli | Traveler’s diarrhea, Watery diarrhea | Profuse watery diarrhea, abdominal cramps, low-grade fever. Leading cause of traveler’s diarrhea. | YES ✓ (Moderate-severe cases) | Shortens illness by 24-36 hours. Azithromycin or rifaximin preferred. |
| EPEC | Enteropathogenic E. coli | Infantile diarrhea, Persistent diarrhea | Watery diarrhea in children <2 years (developing countries). Causes attaching-effacing lesions. | SELECTIVE ⚠️ | Consider only if persistent >2 weeks or severe. Most cases self-limited. |
| EAEC | Enteroaggregative E. coli | Acute & chronic watery diarrhea, Traveler’s diarrhea | Watery diarrhea (can be persistent), low-grade fever. “Stacked brick” appearance on microscopy. | SELECTIVE ⚠️ | Evidence limited. Treat if moderate-severe or persistent. Similar to ETEC. |
| EIEC | Enteroinvasive E. coli | Dysentery-like illness, Inflammatory colitis | Bloody/mucoid diarrhea, fever, severe cramps. Closely related to Shigella. Invades colonic epithelium. | YES ✓ (Severe cases) | Shortens duration and reduces complications. Treat like Shigella. |
| DAEC | Diffusely Adherent E. coli | Watery diarrhea (questionable pathogenicity) | Watery diarrhea in children. Pathogenic role unclear and debated. | NO ❌ | Insufficient evidence of pathogenicity. Supportive care only. |
| UPEC | Uropathogenic E. coli | Urinary tract infections (UTIs), Cystitis, Pyelonephritis | Dysuria, frequency, urgency, flank pain, fever (if pyelonephritis). Most common cause of UTIs. | YES ✓ | Standard UTI treatment. Fluoroquinolones, TMP-SMX, nitrofurantoin, or fosfomycin. |
| NMEC | Neonatal Meningitis E. coli | Neonatal meningitis, Neonatal sepsis | Fever, lethargy, poor feeding in neonates. Possesses K1 capsule enabling CNS invasion. | YES ✓ | Critical. Requires IV cephalosporins (cefotaxime) + aminoglycosides. |
| APEC | Avian Pathogenic E. coli | Avian colibacillosis (birds only) | Respiratory disease, septicemia in poultry. Not typically a human pathogen. | N/A | Veterinary pathogen. Not relevant to human medicine. |
TABLE 2: INTESTINAL vs. EXTRAINTESTINAL E. COLI
| Category | Pathotypes Included | Primary Site | General Approach |
|---|---|---|---|
| Intestinal Pathogenic E. coli (InPEC) | STEC/EHEC, ETEC, EPEC, EAEC, EIEC, DAEC | Gastrointestinal tract | Variable - depends on specific pathotype |
| Extraintestinal Pathogenic E. coli (ExPEC) | UPEC, NMEC, APEC | Urinary tract, Blood, CNS, Respiratory (birds) | Generally requires antibiotics |
TABLE 3: ANTIBIOTIC TREATMENT DECISION TABLE
| Pathotype | Treat with Antibiotics? | First-Line Agent(s) | Dosing | Key Pearl |
|---|---|---|---|---|
| STEC/EHEC | NO - Contraindicated | None - Supportive care + IV hydration | N/A | IV hydration within 4 days reduces HUS risk. Monitor for HUS up to 14 days. |
| ETEC | YES - If moderate-severe | Azithromycin (preferred) OR Rifaximin OR Ciprofloxacin | Azithromycin 500mg x 3d; Rifaximin 200mg TID x 3d | Drug of choice for traveler’s diarrhea. Shortens illness 24-36 hours. |
| EPEC | MAYBE - If persistent >2 weeks | Azithromycin OR TMP-SMX (children) | Azithromycin 10 mg/kg/day x 3d; TMP-SMX 5 mg/kg BID x 5d | Most cases self-limited. Common in developing countries. |
| EAEC | MAYBE - If moderate-severe | Azithromycin (same as ETEC) | Azithromycin 500mg x 3d | Clinical significance debated. Often co-detected with other pathogens. |
| EIEC | YES - If severe | Azithromycin OR Ceftriaxone | Azithromycin 500mg x 3d; Ceftriaxone 1g IV daily | Treat like Shigella - very similar organism. |
| DAEC | NO | None - Supportive care only | N/A | Pathogenicity questionable. Rarely detected clinically. |
| UPEC | YES - Always | Nitrofurantoin, Fosfomycin, TMP-SMX, Fluoroquinolones | Varies by drug and severity (cystitis vs pyelonephritis) | Uncomplicated cystitis: 3-5 days; Pyelonephritis: 7-14 days |
| NMEC | YES - Critical emergency | Cefotaxime + Gentamicin (IV) | Cefotaxime 50 mg/kg Q8-12h + Gentamicin 2.5 mg/kg Q8-12h | High mortality without treatment. Requires LP and blood cultures. |
TABLE 4: VIRULENCE FACTORS BY PATHOTYPE
| Pathotype | Key Virulence Factor(s) | Mechanism of Disease | Diagnostic Marker |
|---|---|---|---|
| STEC/EHEC | Shiga toxin (Stx1, Stx2), LEE pathogenicity island, Intimin (eae) | Toxin inhibits protein synthesis → endothelial damage → HUS | Stx1/Stx2 genes by PCR; Toxin assay |
| ETEC | Heat-labile toxin (LT), Heat-stable toxin (ST), Colonization factors | Toxins increase cAMP/cGMP → secretory diarrhea (cholera-like) | LT/ST genes by PCR |
| EPEC | Bundle-forming pilus (BFP), Intimin (eae gene), LEE pathogenicity island | Attaching-effacing lesions → villous flattening → malabsorption | eae + bfpA genes (typical EPEC); eae only (atypical EPEC) |
| EAEC | Aggregative adherence fimbriae (AAF), AggR regulon, EAST toxin | Forms biofilm on mucosa → persistent colonization and inflammation | AggR gene or AAF genes by PCR |
| EIEC | Invasion plasmid antigens (Ipa), Similar to Shigella virulence | Invades colonic epithelium → inflammation, dysentery | ipaH gene by PCR (similar to Shigella) |
| UPEC | P fimbriae, Type 1 fimbriae, Hemolysin, CNF1 toxin | Adhesion to uroepithelium → ascending infection → inflammation | Culture from urine; No specific virulence testing needed |
| NMEC | K1 capsule, IbeA protein, S fimbriae | K1 capsule evades immune system → bacteremia → CNS invasion | K1 antigen detection; CSF culture |
TABLE 5: INFECTIOUS DOSE & TRANSMISSION ROUTES
| Pathotype | Infectious Dose (CFU) | Primary Transmission Routes | Incubation Period |
|---|---|---|---|
| STEC/EHEC | Very low (10-100) | Undercooked beef (especially ground), unpasteurized milk, contaminated water, petting zoos | 1-8 days (median 3-4 days) |
| ETEC | High (10⁶-10⁸) | Contaminated food/water in developing countries, ice cubes, raw vegetables | 12-72 hours |
| EPEC | Moderate (10⁶) | Contaminated food/water, person-to-person (daycare), fomites | 12-48 hours |
| EAEC | Unknown (likely moderate) | Contaminated food/water, persistent environmental contamination | Variable (1-8 days) |
| EIEC | Low-moderate (10²-10⁴) | Contaminated food/water, person-to-person fecal-oral, similar to Shigella | 12-72 hours |
| UPEC | N/A (ascending infection) | Endogenous (from GI tract to urinary tract), sexual activity, catheterization | Variable |
| NMEC | N/A (vertical transmission) | Maternal GI/vaginal colonization → neonatal infection during delivery | 0-7 days of life |
TABLE 6: GEOGRAPHIC & EPIDEMIOLOGIC PATTERNS
| Pathotype | Geographic Distribution | Primary Age Groups Affected | Special Populations at Risk |
|---|---|---|---|
| STEC/EHEC | Primarily developed countries (North America, Europe, Japan) | All ages, but HUS most common in children <5 and elderly >65 | Children, elderly, immunocompromised |
| ETEC | Worldwide; endemic in developing countries | Adults (travelers from developed countries); Children in endemic areas | International travelers, military personnel |
| EPEC | Developing countries (Sub-Saharan Africa, Asia, Latin America) | Infants and children <2 years | Malnourished children, formula-fed infants |
| EAEC | Worldwide distribution | All ages | HIV/AIDS patients (causes persistent diarrhea) |
| EIEC | Developing countries; sporadic in developed countries | All ages | Travelers to endemic areas |
| UPEC | Worldwide | Women (reproductive age), Elderly men (prostatic disease) | Diabetes, pregnancy, anatomic abnormalities, catheterized patients |
| NMEC | Worldwide | Neonates (especially <7 days) | Premature infants, prolonged rupture of membranes |
TABLE 7: LABORATORY DIAGNOSIS
| Pathotype | Traditional Methods | Molecular Methods | Rapid Tests Available | Clinical Laboratory Availability |
|---|---|---|---|---|
| STEC/EHEC | Culture on sorbitol-MacConkey agar (O157:H7 only) | PCR for Stx1/Stx2 genes | Shiga toxin EIA | High - Most labs test for STEC |
| ETEC | Not routinely cultured | PCR for LT/ST genes | Limited | Low - Requires specialized molecular panels |
| EPEC | Not routinely cultured | PCR for eae, bfpA genes | Limited | Low - Requires molecular GI panels |
| EAEC | Not routinely cultured | PCR for AggR, AAF genes | Limited | Low - Requires molecular GI panels |
| EIEC | Culture (lactose-negative on MacConkey) | PCR for ipaH gene | Limited | Low - Often missed; similar to Shigella |
| UPEC | Standard urine culture | Not routinely needed | Urine dipstick (leukocyte esterase, nitrites) | High - Universally available |
| NMEC | CSF culture, blood culture | PCR for K1 capsule | Blood culture (automated systems) | High - Standard neonatal sepsis workup |
Note: Multiplex molecular GI panels (e.g., BioFire FilmArray GI Panel, BD MAX Enteric panels) now available in many reference labs and can detect ETEC, EPEC, EAEC, EIEC, and STEC simultaneously.
TABLE 8: ANTIBIOTIC RESISTANCE PATTERNS (United States Data)
| Pathotype | High Resistance (>20%) | Moderate Resistance (10-20%) | Low Resistance (<10%) | Universally Susceptible |
|---|---|---|---|---|
| ETEC | Ampicillin (40-70%), Tetracycline (30-50%) | TMP-SMX (10-30%), Fluoroquinolones (10-25%) | Azithromycin (<5%) | Carbapenems, Tigecycline |
| EPEC | Ampicillin (50-70%), TMP-SMX (30-45%) | Fluoroquinolones (5-15%), Cephalosporins (20-30%) | Azithromycin (<5%) | Carbapenems, Fosfomycin, Amikacin, Colistin |
| EAEC | Ampicillin (60-70%), Tetracycline (30-40%) | TMP-SMX (20-30%) | Azithromycin (<10%) | Carbapenems |
| EIEC | Variable (similar to Shigella) | Fluoroquinolones (regional variation) | Azithromycin, Ceftriaxone | Carbapenems |
| UPEC | Ampicillin (40-50%), TMP-SMX (20-30% in some regions) | Fluoroquinolones (10-30%), 1st gen cephalosporins | Nitrofurantoin, Fosfomycin | Carbapenems |
ESBL-Producing E. coli: - Prevalence: 10-40% depending on region and healthcare vs. community-acquired - Affects: EPEC, EAEC, ETEC, UPEC - Confers resistance to: All penicillins, cephalosporins (except cefepime in some cases), monobactams - Remains susceptible to: Carbapenems, tigecycline, colistin (last resort)
CLINICAL DECISION ALGORITHMS
Algorithm 1: Acute Diarrhea After Well Water Exposure
Patient with diarrhea + well water exposure
|
↓
Is diarrhea bloody?
|
┌───────┴───────┐
| |
YES NO
| |
↓ ↓
STEC likely Watery diarrhea
| |
↓ ↓
Order: Mild/self-limited?
- Stool culture |
- Shiga toxin ┌───┴───┐
| |
While pending: YES NO
- NO antibiotics | |
- NO antimotility ↓ ↓
- IV hydration Supportive Moderate-severe?
- Monitor HUS care only |
↓
Consider antibiotics:
- Azithromycin 500mg x 3d
- IF STEC RULED OUT
Algorithm 2: Antibiotic Decision for Confirmed E. coli Pathotype
Confirmed E. coli pathotype identified
|
↓
Which pathotype?
|
┌───────────┼───────────┐
| | |
↓ ↓ ↓
STEC/ ETEC/EAEC/ UPEC/
EHEC EIEC/EPEC NMEC
| | |
↓ ↓ ↓
NO Risk stratify YES
Antibiotics | Antibiotics
| ↓ (Always)
| Severe/persistent/
| high-risk patient?
| |
| ┌─────┴─────┐
| YES NO
| | |
| ↓ ↓
| Antibiotics Supportive
| indicated care only
| |
└──────┴──────────────────→ Treatment complete
CRITICAL TEACHING POINTS
1. The STEC Exception - NEVER FORGET
Why STEC is different: - ONLY E. coli pathotype where antibiotics are CONTRAINDICATED - Antibiotics increase HUS risk from baseline ~6% to ~56% (14-fold increase) - Mechanism: Antibiotics cause bacterial lysis → massive Shiga toxin release → endothelial damage - Even bacteriostatic antibiotics at sub-MIC concentrations increase toxin production
Mnemonic: “STEC = STOP antibiotics”
What DOES work for STEC: - Early IV hydration (within 4 days of symptom onset) - ONLY proven intervention - Close monitoring for HUS (daily CBC, BMP up to 14 days) - Avoid: Antibiotics, antimotility agents, NSAIDs
High-risk STEC features predicting HUS: - Age <5 years or >65 years - High initial WBC count (>15,000) - Stool culture positive early in illness - Stx2 (more virulent than Stx1) - Use of antibiotics
2. Geographic & Travel Considerations
ETEC - “Traveler’s Diarrhea” - Most common cause of traveler’s diarrhea (30-40% of cases) - Endemic in: Latin America, Africa, South Asia, Middle East - Classic scenario: Tourist develops watery diarrhea 2 days into Mexico trip - Prevention: “Boil it, cook it, peel it, or forget it” - Prophylaxis: Generally NOT recommended (promote resistance)
EPEC - “Infantile Diarrhea in Developing Countries” - After rotavirus, leading cause of death in children <2 in developing countries - Rare in developed countries - Important consideration in adopted children from endemic areas - Associated with malnutrition and formula feeding (lack of protective maternal antibodies)
STEC - “The Burger Bug” - Primarily developed countries (USA, Canada, UK, Japan, Germany) - Peak incidence: Summer months (BBQ season) - Outbreaks linked to: Ground beef, unpasteurized milk/juice, swimming pools, petting zoos - Cattle are asymptomatic reservoirs
3. Antibiotic Resistance - Emerging Threats
ESBL-Producing E. coli (20-40% of isolates in some areas): - Confers resistance to most β-lactams (including 3rd generation cephalosporins) - Most common gene: blaCTX-M (CTX-M-15 predominates) - Risk factors: Recent hospitalization, nursing home residence, recent antibiotic use, international travel - Treatment: Carbapenems (ertapenem, meropenem) for severe infections
Fluoroquinolone Resistance (Rising globally): - Campylobacter: 40% in some US regions, >80% in Southeast Asia - ETEC: 10-25% in travelers returning from Asia - Treatment failure rates: 15-30% with ciprofloxacin for traveler’s diarrhea - Alternative: Azithromycin (maintains low resistance <5%)
Why Azithromycin is increasingly preferred: - Low resistance across all diarrheagenic E. coli (<5%) - Safe in pregnancy and children - Once-daily dosing - Does NOT increase STEC toxin production (unlike fluoroquinolones) - Reduces fecal shedding (institutional benefit)
4. Not All E. coli Are Equal
Commensalism vs. Pathogenicity: - ~10⁸-10⁹ E. coli CFU/gram in normal stool - >99% of gut E. coli are BENEFICIAL or neutral - Produce vitamin K2, compete with pathogens, maintain gut homeostasis - Pathogenic E. coli require SPECIFIC virulence factors (toxins, adhesins, invasins)
Cannot distinguish by routine culture: - All E. coli grow on MacConkey agar as pink/red (lactose-fermenting) colonies - Exception: EHEC O157:H7 (sorbitol-negative) and EIEC (lactose-negative) - Requires molecular testing (PCR) or immunoassays to identify pathotypes - Many labs only test for STEC; other pathotypes require specific multiplex panels
Clinical implication: - Stool culture showing “normal flora including E. coli” does NOT rule out pathogenic E. coli - Must specifically order: STEC testing, GI pathogen panel, or send to reference lab
5. Special Populations - Different Rules Apply
Immunocompromised Patients (HIV, chemotherapy, transplant): - EAEC → persistent diarrhea (weeks to months), wasting - Higher risk of bacteremia with any InPEC pathotype - More likely to need antibiotics even for typically self-limited infections - Consider empiric treatment while awaiting cultures
Neonates (<28 days): - NMEC → life-threatening meningitis/sepsis - ANY E. coli bacteremia in neonate warrants LP (20-30% have concurrent meningitis) - Empiric coverage must include E. coli (ampicillin + gentamicin OR cefotaxime) - High mortality (15-40%) even with appropriate treatment
Pregnant Women: - UTIs (UPEC) progress to pyelonephritis more rapidly - Asymptomatic bacteriuria requires treatment (unlike non-pregnant women) - Increased risk of preterm labor with pyelonephritis - Antibiotic choices: Cephalexin, nitrofurantoin (avoid in 3rd trimester), fosfomycin - Avoid: Fluoroquinolones, TMP-SMX in 1st/3rd trimester
Elderly with Atherosclerosis: - Non-typhoidal Salmonella (and E. coli) can seed atherosclerotic plaques - Risk of mycotic aneurysm, endovascular infection - Lower threshold to treat Salmonella bacteremia in elderly - May require prolonged antibiotics (4-6 weeks)
6. Post-Infectious Complications - Think Beyond Acute Illness
Hemolytic Uremic Syndrome (HUS) - STEC: - Triad: Hemolytic anemia + Thrombocytopenia + Acute kidney injury - Occurs 5-10 days after diarrhea onset (as diarrhea resolving) - Most common cause of acute renal failure in children - 3-5% mortality, 12% develop ESRD, 25% have long-term renal sequelae - No specific treatment - supportive care, dialysis if needed - Avoid platelet transfusions unless life-threatening bleeding (may worsen thrombotic microangiopathy)
Reactive Arthritis (Reiter’s Syndrome): - Follows EIEC, Shigella, Salmonella, Campylobacter infections - Classic triad: Arthritis + Urethritis + Conjunctivitis (“Can’t see, can’t pee, can’t climb a tree”) - Strongly associated with HLA-B27 - Onset: 1-3 weeks after GI infection resolves - Treatment: NSAIDs, sometimes DMARDs if persistent
Guillain-Barré Syndrome (GBS): - Most commonly follows Campylobacter (but can follow other GI infections) - Molecular mimicry: Bacterial lipooligosaccharides cross-react with gangliosides in peripheral nerves - Onset: 1-3 weeks after infection - Ascending paralysis, areflexia, potential respiratory failure - Treatment: IVIG or plasmapheresis
Post-Infectious IBS (PI-IBS): - Develops in 10-15% of patients after acute bacterial gastroenteritis - Risk factors: Female sex, younger age, severity of acute illness, psychological stress - Symptoms persist >6 months after infection clears - Treatment: Standard IBS management (dietary, probiotics, antispasmodics)
7. Laboratory Pearls - Optimizing Diagnosis
When to order what:
| Clinical Scenario | Test to Order | Rationale |
|---|---|---|
| Bloody diarrhea | Stool culture + Shiga toxin assay (or STEC PCR) | MUST rule out STEC before giving antibiotics |
| Watery diarrhea + fever | Stool culture for Salmonella, Shigella, Campylobacter | Standard bacterial pathogens |
| Traveler’s diarrhea | Consider GI multiplex PCR panel | Detects ETEC, EAEC, parasites; faster than culture |
| Persistent diarrhea (>7 days) | GI multiplex panel + ova & parasites x3 | EPEC, EAEC, Giardia, Cryptosporidium |
| HIV patient with chronic diarrhea | Comprehensive testing: GI panel, O&P, mycobacterial culture, CMV | Multiple opportunistic pathogens possible |
| Outbreak investigation | Stool culture + save isolates for serotyping/PFGE | Need isolates for epidemiologic analysis |
Multiplex GI Panels (BioFire, Luminex, BD MAX): - Pros: Rapid (1-2 hours), detects multiple pathogens simultaneously, high sensitivity - Cons: Expensive ($200-400), may detect colonization vs. true infection, not all labs have - What they detect: STEC, ETEC, EPEC, EAEC, EIEC + Salmonella, Shigella, Campylobacter, viruses, parasites - Clinical use: Consider for severe illness, immunocompromised, outbreak, negative routine culture
8. Supportive Care - Never Forget the Basics
Hydration is the cornerstone: - Prevents dehydration-related mortality (especially children, elderly) - Oral rehydration solution (ORS) preferred if patient can tolerate PO - WHO ORS formula: Na+ 75 mEq/L, glucose 75 mmol/L (promotes Na-glucose cotransport) - IV fluids if: Severe dehydration, hemodynamic instability, intractable vomiting, altered mental status
What NOT to do: - Antimotility agents (loperamide, diphenoxylate) with bloody diarrhea or fever - Can precipitate toxic megacolon - Increase risk of HUS with STEC - Prolong illness with invasive pathogens (Shigella, EIEC) - Bismuth subsalicylate in children <12 years (Reye’s syndrome risk) - NSAIDs in suspected STEC (may worsen renal injury)
Nutrition: - Resume normal diet as soon as tolerated (including regular dairy if tolerated) - BRAT diet (bananas, rice, applesauce, toast) is outdated - insufficient calories/protein - Continue breastfeeding in infants - Small, frequent meals if nausea/cramping prominent
Probiotics: - Evidence mixed; generally safe - Possible benefit: Lactobacillus GG, Saccharomyces boulardii - Do NOT give if immunocompromised (risk of fungemia with S. boulardii)
9. Public Health & Reporting Requirements
Reportable Conditions (varies by state, but commonly include): - STEC/EHEC infection (ALL cases) - Hemolytic Uremic Syndrome - Shigellosis - Salmonellosis - Campylobacteriosis - Outbreaks (≥2 linked cases)
When to report: - Suspicion is sufficient - definitive diagnosis NOT required - Report to local/state health department within 24-48 hours - Helps identify outbreaks, contaminated food sources, common exposures - Health department may require follow-up stool cultures to clear food handlers
High-risk occupations requiring clearance: - Food handlers - Healthcare workers (direct patient care) - Daycare workers - Usually require 2 negative stool cultures ≥24 hours apart, ≥48 hours after antibiotic completion
10. Prevention Strategies - Patient Counseling
For patients with well water: - Annual testing for coliforms (minimum) - Test more frequently if: Nearby contamination, heavy rain/flooding, pregnant/infant in home - Shock chlorination after positive result - Consider UV treatment or filtration system - Safe distance: Well ≥50 feet from septic system, livestock
Food safety: - Cook ground beef to 160°F (71°C) - use meat thermometer - Avoid raw milk and raw milk products - Wash produce thoroughly, especially leafy greens - Separate cutting boards for raw meat and produce - Refrigerate promptly (<2 hours, <1 hour if >90°F)
Travel advice (ETEC prevention): - “Boil it, cook it, peel it, or forget it” - Avoid: Ice, tap water, raw vegetables, street food, buffets - Safe: Bottled water (sealed), hot coffee/tea, beer, wine, freshly cooked food - Consider taking azithromycin or rifaximin for self-treatment (not prophylaxis) - Prophylactic antibiotics NOT routinely recommended (promotes resistance)
SUMMARY: KEY DECISION POINTS
When Patient Has Diarrhea + Well Water Exposure:
1. Is it bloody diarrhea? - YES → Suspect STEC → DO NOT give antibiotics → Order Shiga toxin test + culture - NO → Continue evaluation
2. Is there fever or severe illness? - YES → Consider bacterial pathogen → Order stool culture - NO → Likely viral or mild bacterial → Supportive care
3. Is STEC ruled out (negative Shiga toxin + culture)? - YES → Can consider antibiotics if indicated by pathogen/severity - NO → Continue to withhold antibiotics
4. Which pathogen is identified? - Shigella → Give antibiotics (azithromycin) - Campylobacter → Risk stratify → Give if high-risk - Salmonella → Risk stratify → Usually no antibiotics unless high-risk - ETEC/EAEC/EIEC/EPEC → Assess severity → Consider antibiotics if moderate-severe
5. Patient is asymptomatic but worried about exposure? - NO prophylactic antibiotics - Education about symptoms to watch for - Reassurance that most exposures don’t cause illness
REFERENCES & RESOURCES
Key Guidelines: 1. IDSA 2017 Clinical Practice Guidelines for Infectious Diarrhea 2. CDC Guidelines for STEC Infections 3. WHO Guidelines for Diarrheal Disease Management
Useful Websites: - CDC E. coli Information: www.cdc.gov/ecoli - Travelers’ Health (Traveler’s Diarrhea): wwwnc.cdc.gov/travel - State Health Department Well Water Testing Resources
Continuing Education: - ID Board Review Courses (IDSA, Mayo Clinic) - CDC Laboratory Training Courses - APHL (Association of Public Health Laboratories) Resources
ACRONYMS & ABBREVIATIONS
- AAF = Aggregative Adherence Fimbriae
- APEC = Avian Pathogenic E. coli
- BFP = Bundle-Forming Pilus
- CFU = Colony Forming Units
- DAEC = Diffusely Adherent E. coli
- EAEC = Enteroaggregative E. coli
- EHEC = Enterohemorrhagic E. coli
- EIEC = Enteroinvasive E. coli
- EPEC = Enteropathogenic E. coli
- ESBL = Extended-Spectrum Beta-Lactamase
- ETEC = Enterotoxigenic E. coli
- ExPEC = Extraintestinal Pathogenic E. coli
- GBS = Guillain-Barré Syndrome
- HUS = Hemolytic Uremic Syndrome
- InPEC = Intestinal Pathogenic E. coli
- LEE = Locus of Enterocyte Effacement
- LT = Heat-Labile Toxin
- NMEC = Neonatal Meningitis E. coli
- ORS = Oral Rehydration Solution
- PI-IBS = Post-Infectious Irritable Bowel Syndrome
- ST = Heat-Stable Toxin
- STEC = Shiga Toxin-Producing E. coli
- Stx = Shiga Toxin
- TMP-SMX = Trimethoprim-Sulfamethoxazole
- UPEC = Uropathogenic E. coli
- UTI = Urinary Tract Infection
DOCUMENT INFORMATION
Created: 2025 Purpose: Physician reference for E. coli pathotype classification and treatment Based on: Iowa well water contamination exposure case discussion Evidence Level: Based on CDC guidelines, IDSA guidelines, and peer-reviewed literature Last Updated: October 2025
This document is intended for educational purposes for healthcare professionals. Clinical decisions should be individualized based on patient presentation, local epidemiology, and resistance patterns.